Fibrin glue for wound repair: facts and fancy

Summary

In wound repair, fibrin has a multiplicity of activities, some of which are intrinsic to the protein itself and some attributable to other blood constituents associated with the fibrin clot. Fibrin sealants, which have been approved for hemostasis in the US and Europe, are occasionally used wounds to promote healing. However, inconsistency exists in the literature regarding the benefit of these preparations in the healing process. Morecrude fibrinogen preparations, such as cryoprecipitates made from the patient’s own blood on location, appear from the literature to have better utility in wounds than more purified fibrinogen preparations available through commercial sources. These divergent outcomes are likely attributable to additional blood-derived products being associated with cryo-precipitates compared to the relatively purified commercial fibrinogen preparations. Clearly standard preparations and methods of application of fibrin sealant need to be defined for each particular surgical setting to resolve the many ostensible discrepancies in the current literature. A corollary is that different fibrin sealant preparations are likely to be preferable for different clinical situations.

Keywords

Fibrin sealant - fibronectin - cell migration - wound healing

• References

• 1 Drew AF, Liu H, Davidson JM. et al. Wound-healing defects in mice lacking fibrinogen. Blood 2001; 97: 3691-8.
• 2 Chan JC, Duszczyszyn DA, Castellino FJ. et al. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001; 159: 1681-8.
• 3 Clark, RAF. Fibrin is a many splendored thing. J Invest Dermatol. 2003 121. in press.
• 4 Clark RAF. Fibrin and wound healing. Ann N Y Acad Sci 2001; 936: 355-67.
• 5 Van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001; 936: 426-37.
• 6 Kawase T, Okuda K, Wolff LF. et al. Platelet-rich plasma-derived fibrin clot formation stimulates collagen synthesis in periodontal ligament and osteoblastic cells in vitro. J Peroiodontol 2003; 74: 858-64.
• 7 Nien YD, Han YP, Tawai B. et al. Fibrinogen inhibits fibroblast-mediated contracton of collagen. Wound Repair Regen 2003; 11: 380-5.
• 8 Geer DJ, Swartz DD, Andreadis ST. Fibrin promotes migration in a three-dimensional in vitro model of wound regeneration. 2002; 8: 787-98.
• 9 Clark RAF. Fibrin sealant in wound repair: a systematic survey of the literature. Expert Opin Investig Drugs 2000; 9: 2371-92.
• 10 de Virgilio C, Dubrow T, Sheppard BB. et al. Fibrin glue inhibits intra-abdominal adhesion formation. Arch Surg 1990; 125: 1378-81 discussion 1381-2
• 11 Sheppard BB, De Virgilio C, Bleiweis M. et al. Inhibition of intra-abdominal adhesions: fibrin glue in a long term model. Am Surg 1993; 59: 786-90.
• 12 Takeuchi H, Toyonari Y, Mitsuhashi N. et al. Effects of fibrin glue on postsurgical adhesions after uterine or ovarian surgery in rabbits. J Obstet Gynaecol Res 1997; 23: 479-84.
• 13 Frykman E, Jacobsson S, Widenfalk B. Fibrin sealant in prevention of flexor tendon adhesions: an experimental study in the rabbit. J Hand Surg [Am] 1993; 18: 68-75.
• 14 Moro H, Hayashi J, Ohzeki H. et al. The effect of fibrin glue on inhibition of pericardial adhesions. Jpn J Thorac Cardiovasc Surg 1999; 47: 79-84.
• 15 Donnez J, Nisolle M. Laparoscopic management of large ovarian endometrial cyst: use of fibrin sealant. J Gynecol Surg 1991; 7: 163-6.
• 16 Eroglu E, Oral S, Unal E. et al. Reducing seroma formation with fibrin glue in an animal mastectomy model. Eur J Surg Oncol 1996; 22: 137-9.
• 17 Harada RN, Pressler VM, McNamara JJ. Fibrin glue reduces seroma formation in the rat after mastectomy. Surg Gynecol Obstet 1992; 175: 450-4.
• 18 Sanders RP, Goodman NC, Amiss Jr. LR. et al. Effect of fibrinogen and thrombin concentrations on mastectomy seroma prevention. J Surg Res 1996; 61: 65-70.
• 19 Uden P, Aspegren K, Balldin G. et al. Fibrin adhesive in radical mastectomy. Eur J Surg 1983; 159: 263-5.
• 20 Vaxman F, Kolbe A, Stricher F. et al. Does fibrin glue improve drainage after axillary lymph node dissection? Prospective and ran-domized study in humans. Eur Surg Res 1995; 27: 346-52.
• 21 Gilly FN, Francois Y, Sayag-Beaujard AC. et al. Prevention of lymphorrhea by means of fibrin glue after axillary lymphadenectomy in breast cancer: prospective randomized trial. Eur Surg Res 1998; 30: 439-43.
• 22 Moore MM, Nguyen DH, Spotnitz WD. Fibrin sealant reduces serous drainage and allows for earlier drain removal after axillary dissection: a randomized prospective trial. Am Surg 1997; 63: 97-102.
• 23 Dinsmore RC, Harris JA. Gustafson RJ. Effect of fibrin glue on lymphatic drainage after modified radical mastectomy: a prospective randomized trial. Am Surg 2000; 66: 982-5.
• 24 Langer S, Guenther JM, DiFronzo LA. Does fibrin sealant reduce drain output and allow earlier removal of drainage catheters in women undergoing operation for breast cancer?. Am Surg 2003; 69: 77-81.
• 25 Moore M, Burak Jr. WE, Nelson E. et al. Fibrin sealant reduces the duration and amount of fluid drainage after axillary dissection: a randomized prospective clinical trial. J Am Coll Surg 2001; 192: 591-9.
• 26 Giovannacci L, Renggli JC, Eugster T. et al. Reduction of groin lymphatic complications by application of fibrin glue: preliminary results of a randomized study. Ann Vasc Surg 2001; 15: 182-5.
• 27 Scholz HS, Petru E, Benedicic C. et al. Fibrin application for preventing lymphocysts after retroperitoneal lymphadenectomy in patients with gynecologic malignancies. Gynecol Oncol 2002; 84: 43-6.
• 28 Yamada KM, Clark RAF. Provisional matrix. In Molecular and Cellular Biology of Wound Repair. Clark, R. A. F., editor. Plenum, New York 1996; 51-93.
• 29 Clark RAF. Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J Invest Dermatol 1990; 94 Suppl 128S-134S.
• 30 Clark RAF, An J-Q, Greiling D. et al. Fibroblast migration on fibronectin requires 3 distinct functional domains. J Invest Dermatol 2003 in press.
• 31 Herrick SE, Sloan P, McGurk M. et al. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Path 1992; 141: 1085-95.
• 32 Greiling D, Clark RAF. Fibronectin provides a conduit for fibroblast transmigration from a collagen gel into a fibrin gel. J Cell Sci 1997; 110: 861-70.
• 33 Mosesson MW, Umfleet R. The cold insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold insoluble fraction components. J Biol Chem 1970; 245: 5726-36.
• 34 Clark RAF, Lanigan JM, DellaPelle P. et al. Fibronectin and fibrin(ogen) provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol 1982; 79: 264-9.
• 35 Tuszynski GP, Srivastava S, Switalska I H. et al. The interaction of human platelet thrombospondin with fibrinogen. Thrombospondin purification and specificity of interaction. J Biol Chem 1985; 260: 12240-5.
• 36 Dixit VM, Grant GA, Frazier WA. et al. Isolation of the fibrinogen-binding region of platelet thrombospondin. Biochem Biophys Res Commun 1984; 119: 1075-81.
• 37 Bacon-Baguley T, Ogilvie ML, Gartner TK. et al. Thrombospondin binding to specific sequences within the A alpha- and B beta-chains of fibrinogen. J Biol Chem 1990; 265: 2317-23.
• 38 Preissner KT, Jenne D. Vitronectins. A new molecular connection in haemostasis. Thromb Haemost 1991; 66: 189-94.
• 39 Odrljin TM, Shainoff JR, Lawrence SO. et al. Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood 1996; 88: 2050-61.
• 40 Castellino FJ, Strickland DK, Morris JP. et al. Enhancement of the streptokinase-induced activation of human plasminogen by human fibrinogen and human fibrinogen fragment D1. Ann NY Acad Sci 1983; 408: 595-601.
• 41 Thorsen S, Glas-Greenwalt P, Astrup T. Difference in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Pathol Haem 1972; 28: 65-74.
• 42 Wagner OF, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1989; 70: 1645-53.
• 43 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-5.
• 44 Wilner GD, Danitz MP, Mudd MS. et al. Selective immobilization of alpha-thrombin by surface-bound fibrin. J Lab Clin Med 1981; 97: 403-11.
• 45 Kaminski M, McDonagh J. Studies on the mechanism of thrombin interaction with fibrin. J Biol Chem 1983; 258: 10530-5.
• 46 Siebenlist KR, DiOrio JP, Budzynski AZ. et al. The polymerization and thrombin-binding properties of des-(Bb1-42)-fibrin. J Biol Chem 1990; 265: 18650-5.
• 47 Sahni A, Odrljin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998; 273: 7554-9.
• 48 Campbell PG, Durham SK, Hayes JD. et al. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 1999; 274: 30215-21.
• 49 Sahni A, Francis C W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96: 3772-8.
• 50 Sakata Y, Aoki N. Cross-linking of α2-plasma inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
• 51 Zisch AH, Schenk JC, Sakiyama-Elbert SE. Covalently conjugated VEGF-fibrin matricess for endothelialization. J Control Release 2001; 72: 101-13.
• 52 Wong C, Inman E, Spaethe R. Fibrin-based biomaterials to deliver human growth factors. Thromb Haemost 2003; 89: 573-82.